KALILACTASOL Unknown
Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Summary of Product characteristics
(SPC)
12-05-2024
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
SODIUM CHLORIDE CALCIUM CHLORIDE DIHYDRATE MAGNESIUM CHLORIDE HEXAHYDRATE POTASSIUM CHLORIDE SODIUM LACTATE GLUCOSE
Available from:
Gambro Lundia AB
Pharmaceutical form:
Unknown
Authorization date:
2004-11-19
Summary of Product characteristics
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Kalilactasol, solution for haemofiltration and haemodialysis
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
3 PHARMACEUTICAL FORM
Solution for haemofiltration and haemodialysis.
Clear solution with a slightly yellow colour.
pH of the solution: 4.5 – 6.5
Theoretical Osmolarity: 301.6 mOsm/l
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
As a substitution solution in continuous haemofiltration and haemodiafiltration and as dialysis solution in continuous
haemodialysis and haemodiafiltration for acute renal failure and in cases of drug poisoning with dialysable or filterable
substances.
Kalilactasol is particularly indicated in patients who have a tendency to hyperkalaemia.
Sodium Chloride
5.961
g/l
Calcium Chloride (Dihydrate)
0.257
g/l
Magnesium Chloride (Hexahydrate)
0.152
g/l
Potassium Chloride
0.149
g/l
Sodium Lactate solution 60% w/w
7.471
g/l
corresponding to Sodium Lactate anhydrous
4.483
g/l
Glucose Anhydrous
1.100
g/l
(in Glucose Monohydrate
1.210
g/l)
Kalilactasol solution contains glucose anhydrous 1.1g/litre and in mmol per litre:
Sodium
142.00
Chloride
109.00
Potassium
2.00
Calcium
1.75
Magnesium
0.75
Lactate
40.00
For a full list of excipients, see section 6.1
IRISH MEDICINES BOARD
________________________________________________________________________________________________________________________
_Date Printed 12/03/2012_
_CRN 2099824_
_page number: 1_
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
Kalilactasol is administered into the venous return of the patient.
Kalilactasol, when used as a substitution solution, is administered into the circuit before (pre-dilution) or after the
hemofilter (post-dilution).
The volume of the solution administered will depend upon the fluid balance of the individual patient, the target fluid
balance to be achieved and the amount
Read the complete document
